BioSpace News Archive

Transnetyx, a global leader in outsourced genetic services, announced the acquisition of Laragen, a sequencing and genetic services company in Culver City, CA.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced updated data from GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study in second-line advanced hepatocellular carcinoma (HCC).

Advanced NanoTherapies Inc. announced a $4M Series A extension from a prominent undisclosed strategic medical device company.

SRP-001, a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics

Inhibikase Therapeutics, Inc. today announced that Milton Werner Ph.D., President and Chief Executive Officer of Inhibikase, will deliver two oral presentations at the International Congress of Parkinson’s Disease and Movement Disorders. The event is being held in Copenhagen, Denmark, between August 27-31, 2023.

Wenzel Spine, Inc. is pleased to announce the recent FDA clearance for their primaLOK SP System.

Ventus Therapeutics announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.

Nascent Biotech, Inc. announced today that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer.

Akava Therapeutics, Inc. announced On July 3rd, the U.S. Food and Drug Administration cleared Akava’s Investigational New Drug (IND) application for the treatment of amyotrophic lateral sclerosis (ALS) to proceed with a Phase I first-in-human study in healthy subjects using Akava’s investigational new drug, AKV9 (formerly NU-9).

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).